Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2+ Breast Cancer.

Yu X, Ghamande S, Liu H, Xue L, Zhao S, Tan W, Zhao L, Tang SC, Wu D, Korkaya H, Maihle NJ, Liu HY.

Mol Ther Nucleic Acids. 2018 Mar 2;10:317-330. doi: 10.1016/j.omtn.2017.12.015. Epub 2017 Dec 30.

2.

Malignant pericytes expressing GT198 give rise to tumor cells through angiogenesis.

Zhang L, Wang Y, Rashid MH, Liu M, Angara K, Mivechi NF, Maihle NJ, Arbab AS, Ko L.

Oncotarget. 2017 May 25;8(31):51591-51607. doi: 10.18632/oncotarget.18196. eCollection 2017 Aug 1.

3.

Enhancing diversity in the hematology biomedical research workforce: A mentoring program to improve the odds of career success for early stage investigators.

Pace BS, Makala LH, Sarkar R, Liu L, Takezaki M, Mohandas N, Dixon G, Werner EM, Jeffe DB, Rice TK, Maihle NJ, González J.

Am J Hematol. 2017 Dec;92(12):1275-1279. doi: 10.1002/ajh.24899. Epub 2017 Sep 25. No abstract available.

PMID:
28857249
4.

Metformin alters DNA methylation genome-wide via the H19/SAHH axis.

Zhong T, Men Y, Lu L, Geng T, Zhou J, Mitsuhashi A, Shozu M, Maihle NJ, Carmichael GG, Taylor HS, Huang Y.

Oncogene. 2017 Apr 27;36(17):2345-2354. doi: 10.1038/onc.2016.391. Epub 2016 Oct 24.

5.

A Perspective on Promoting Diversity in the Biomedical Research Workforce: The National Heart, Lung, and Blood Institute's PRIDE Program.

Boyington JE, Maihle NJ, Rice TK, Gonzalez JE, Hess CA, Makala LH, Jeffe DB, Ogedegbe G, Rao DC, Dávila-Román VG, Pace BS, Jean-Louis G, Boutjdir M.

Ethn Dis. 2016 Jul 21;26(3):379-86. doi: 10.18865/ed.26.3.379.

6.

GT198 Expression Defines Mutant Tumor Stroma in Human Breast Cancer.

Yang Z, Peng M, Cheng L, Jones K, Maihle NJ, Mivechi NF, Ko L.

Am J Pathol. 2016 May;186(5):1340-50. doi: 10.1016/j.ajpath.2016.01.006. Epub 2016 Mar 18.

7.

A Federated Network for Translational Cancer Research Using Clinical Data and Biospecimens.

Jacobson RS, Becich MJ, Bollag RJ, Chavan G, Corrigan J, Dhir R, Feldman MD, Gaudioso C, Legowski E, Maihle NJ, Mitchell K, Murphy M, Sakthivel M, Tseytlin E, Weaver J.

Cancer Res. 2015 Dec 15;75(24):5194-201. doi: 10.1158/0008-5472.CAN-15-1973. Review.

8.

Reduced expression of the epidermal growth factor signaling system in preeclampsia.

Armant DR, Fritz R, Kilburn BA, Kim YM, Nien JK, Maihle NJ, Romero R, Leach RE.

Placenta. 2015 Mar;36(3):270-8. doi: 10.1016/j.placenta.2014.12.006. Epub 2014 Dec 27.

9.

Shedding of soluble epidermal growth factor receptor (sEGFR) is mediated by a metalloprotease/fibronectin/integrin axis and inhibited by cetuximab.

Wilken JA, Perez-Torres M, Nieves-Alicea R, Cora EM, Christensen TA, Baron AT, Maihle NJ.

Biochemistry. 2013 Jul 2;52(26):4531-40. doi: 10.1021/bi400437d. Epub 2013 Jun 21.

PMID:
23731208
10.

Transient anabolic effects accompany epidermal growth factor receptor signal activation in articular cartilage in vivo.

Shepard JB, Jeong JW, Maihle NJ, O'Brien S, Dealy CN.

Arthritis Res Ther. 2013;15(3):R60.

11.

A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study.

Leslie KK, Sill MW, Fischer E, Darcy KM, Mannel RS, Tewari KS, Hanjani P, Wilken JA, Baron AT, Godwin AK, Schilder RJ, Singh M, Maihle NJ.

Gynecol Oncol. 2013 Jun;129(3):486-94. doi: 10.1016/j.ygyno.2013.02.019. Epub 2013 Feb 21.

12.

Soluble Human Epidermal Growth Factor Receptor 2 (sHER2) as a Potential Risk Assessment, Screening, and Diagnostic Biomarker of Lung Adenocarcinoma.

Cosentino-Boehm AL, Lafky JM, Greenwood TM, Kimbler KD, Buenafe MC, Wang Y, Branscum AJ, Yang P, Maihle NJ, Baron AT.

Diagnostics (Basel). 2013 Jan 14;3(1):13-32. doi: 10.3390/diagnostics3010013.

13.

Lin28 regulates BMP4 and functions with Oct4 to affect ovarian tumor microenvironment.

Ma W, Ma J, Xu J, Qiao C, Branscum A, Cardenas A, Baron AT, Schwartz P, Maihle NJ, Huang Y.

Cell Cycle. 2013 Jan 1;12(1):88-97. doi: 10.4161/cc.23028. Epub 2012 Dec 19.

14.

Lin28 regulates HER2 and promotes malignancy through multiple mechanisms.

Feng C, Neumeister V, Ma W, Xu J, Lu L, Bordeaux J, Maihle NJ, Rimm DL, Huang Y.

Cell Cycle. 2012 Jul 1;11(13):2486-94. doi: 10.4161/cc.20893. Epub 2012 Jul 1.

PMID:
22713243
15.

EGFR/HER-targeted therapeutics in ovarian cancer.

Wilken JA, Badri T, Cross S, Raji R, Santin AD, Schwartz P, Branscum AJ, Baron AT, Sakhitab AI, Maihle NJ.

Future Med Chem. 2012 Mar;4(4):447-69. doi: 10.4155/fmc.12.11. Review.

16.

The epidermal growth factor receptor conundrum.

Wilken JA, Baron AT, Maihle NJ.

Cancer. 2011 Jun 1;117(11):2358-60. doi: 10.1002/cncr.25805. Epub 2010 Dec 14. No abstract available.

17.

Identification of immunoreactive regions of homology between soluble epidermal growth factor receptor and α5-integrin.

Wilken JA, Baron AT, Foty RA, McCormick DJ, Maihle NJ.

Biochemistry. 2011 May 24;50(20):4309-21. doi: 10.1021/bi200126j. Epub 2011 Apr 27.

18.

Primary trastuzumab resistance: new tricks for an old drug.

Wilken JA, Maihle NJ.

Ann N Y Acad Sci. 2010 Oct;1210:53-65. doi: 10.1111/j.1749-6632.2010.05782.x.

19.

EGFR isoforms and gene regulation in human endometrial cancer cells.

Albitar L, Pickett G, Morgan M, Wilken JA, Maihle NJ, Leslie KK.

Mol Cancer. 2010 Jun 25;9:166. doi: 10.1186/1476-4598-9-166.

20.

Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics.

Wilken JA, Webster KT, Maihle NJ.

J Ovarian Res. 2010 Mar 27;3:7. doi: 10.1186/1757-2215-3-7.

21.

Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer.

Peng S, Maihle NJ, Huang Y.

Oncogene. 2010 Apr 8;29(14):2153-9. doi: 10.1038/onc.2009.500. Epub 2010 Jan 25.

PMID:
20101213
22.

Searching for a system: the quest for ovarian cancer biomarkers.

Rodland KD, Maihle NJ.

Cancer Biomark. 2010-2011;8(4-5):223-30. doi: 10.3233/CBM-2011-0216. Review.

PMID:
22045355
23.

Soluble epidermal growth factor receptor: a biomarker of epithelial ovarian cancer.

Baron AT, Lafky JM, Boardman CH, Cora EM, Buenafe MC, Liu D, Rademaker A, Fishman DA, Podratz KC, Reiter JL, Maihle NJ.

Cancer Treat Res. 2009;149:189-202. doi: 10.1007/978-0-387-98094-2_9. Review. No abstract available.

PMID:
19763437
24.

Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer.

Baron AT, Wilken JA, Haggstrom DE, Goodrich ST, Maihle NJ.

IDrugs. 2009 May;12(5):302-8. Review.

PMID:
19431095
25.

Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells.

Narayan M, Wilken JA, Harris LN, Baron AT, Kimbler KD, Maihle NJ.

Cancer Res. 2009 Mar 15;69(6):2191-4. doi: 10.1158/0008-5472.CAN-08-1056. Epub 2009 Mar 10.

26.

Shedding of epidermal growth factor receptor is a regulated process that occurs with overexpression in malignant cells.

Perez-Torres M, Valle BL, Maihle NJ, Negron-Vega L, Nieves-Alicea R, Cora EM.

Exp Cell Res. 2008 Oct 1;314(16):2907-18. doi: 10.1016/j.yexcr.2008.07.013. Epub 2008 Jul 25.

PMID:
18687326
27.

Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer.

Lafky JM, Wilken JA, Baron AT, Maihle NJ.

Biochim Biophys Acta. 2008 Apr;1785(2):232-65. doi: 10.1016/j.bbcan.2008.01.001. Epub 2008 Feb 7. Review.

PMID:
18291115
28.

Effects of high-fat diet and/or body weight on mammary tumor leptin and apoptosis signaling pathways in MMTV-TGF-alpha mice.

Dogan S, Hu X, Zhang Y, Maihle NJ, Grande JP, Cleary MP.

Breast Cancer Res. 2007;9(6):R91.

29.

Requirement for ErbB2/ErbB signaling in developing cartilage and bone.

Fisher MC, Clinton GM, Maihle NJ, Dealy CN.

Dev Growth Differ. 2007 Aug;49(6):503-13. Epub 2007 Jun 7.

PMID:
17555517
30.

Prevention of mammary tumorigenesis by intermittent caloric restriction: does caloric intake during refeeding modulate the response?

Cleary MP, Hu X, Grossmann ME, Juneja SC, Dogan S, Grande JP, Maihle NJ.

Exp Biol Med (Maywood). 2007 Jan;232(1):70-80.

PMID:
17202587
31.

Therapeutic potential of epidermal growth factor receptor-related protein.

Reiter JL, Maihle NJ, Clinton GM.

Mol Cancer Ther. 2006 Nov;5(11):2954; author reply 2955. No abstract available.

32.

Soluble epidermal growth factor receptor acridinium-linked immunosorbent assay.

Lafky JM, Baron AT, Maihle NJ.

Methods Mol Biol. 2006;327:39-47.

PMID:
16780211
33.

The granulin-epithelin precursor is a steroid-regulated growth factor in endometrial cancer.

Jones MB, Houwink AP, Freeman BK, Greenwood TM, Lafky JM, Lingle WL, Berchuck A, Maxwell GL, Podratz KC, Maihle NJ.

J Soc Gynecol Investig. 2006 May;13(4):304-11.

PMID:
16697948
34.

Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole.

Lafky JM, Baron AT, Cora EM, Hillman DW, Suman VJ, Perez EA, Ingle JN, Maihle NJ.

Cancer Res. 2005 Apr 15;65(8):3059-62.

35.

Studies on epidermal growth factor receptor signaling in vertebrate limb patterning.

Omi M, Fisher M, Maihle NJ, Dealy CN.

Dev Dyn. 2005 Jun;233(2):288-300.

36.

Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.

Baron AT, Boardman CH, Lafky JM, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):306-18. Erratum in: Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1583.

37.

Diet-induced obesity and mammary tumor development in MMTV-neu female mice.

Cleary MP, Grande JP, Juneja SC, Maihle NJ.

Nutr Cancer. 2004;50(2):174-80.

PMID:
15623464
38.

Effect of high fat diet on body weight and mammary tumor latency in MMTV-TGF-alpha mice.

Cleary MP, Grande JP, Maihle NJ.

Int J Obes Relat Metab Disord. 2004 Aug;28(8):956-62.

PMID:
15254485
39.

Membrane localization of v-ErbB is required but not sufficient for ligand-independent transformation.

Danielsen AJ, Christensen TA, Lovejoy CA, Adelsman MA, Connolly DC, Maihle NJ.

Exp Cell Res. 2004 Jun 10;296(2):285-93.

PMID:
15149858
40.

Leptin receptor-deficient MMTV-TGF-alpha/Lepr(db)Lepr(db) female mice do not develop oncogene-induced mammary tumors.

Cleary MP, Juneja SC, Phillips FC, Hu X, Grande JP, Maihle NJ.

Exp Biol Med (Maywood). 2004 Feb;229(2):182-93.

PMID:
14734797
41.

Amphiregulin expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 93 cases.

Bostwick DG, Qian J, Maihle NJ.

Prostate. 2004 Feb 1;58(2):164-8.

PMID:
14716741
42.

Grb2 regulation of the actin-based cytoskeleton is required for ligand-independent EGF receptor-mediated oncogenesis.

Boerner JL, Danielsen AJ, Lovejoy CA, Wang Z, Juneja SC, Faupel-Badger JM, Darce JR, Maihle NJ.

Oncogene. 2003 Oct 2;22(43):6679-89.

PMID:
14555981
43.

Characterization and expression of novel 60-kDa and 110-kDa EGFR isoforms in human placenta.

Reiter J, Maihle NJ.

Ann N Y Acad Sci. 2003 May;995:39-47. Review.

PMID:
12814937
44.

Effect of moderate caloric restriction and/or weight cycling on mammary tumor incidence and latency in MMTV-Neu female mice.

Pape-Ansorge KA, Grande JP, Christensen TA, Maihle NJ, Cleary MP.

Nutr Cancer. 2002;44(2):162-8.

PMID:
12734063
45.

Ligand-independent oncogenic signaling by the epidermal growth factor receptor: v-ErbB as a paradigm.

Boerner JL, Danielsen A, Maihle NJ.

Exp Cell Res. 2003 Mar 10;284(1):111-21. Review.

PMID:
12648470
46.

Genetically obese MMTV-TGF-alpha/Lep(ob)Lep(ob) female mice do not develop mammary tumors.

Cleary MP, Phillips FC, Getzin SC, Jacobson TL, Jacobson MK, Christensen TA, Juneja SC, Grande JP, Maihle NJ.

Breast Cancer Res Treat. 2003 Feb;77(3):205-15.

PMID:
12602920
47.

Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer.

Baron AT, Cora EM, Lafky JM, Boardman CH, Buenafe MC, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):103-13.

48.

Leptin--a growth factor in normal and malignant breast cells and for normal mammary gland development.

Hu X, Juneja SC, Maihle NJ, Cleary MP.

J Natl Cancer Inst. 2002 Nov 20;94(22):1704-11.

PMID:
12441326
49.
50.

Generation and characterization of polyclonal antibodies specific for human p110 sEGFR.

Christensen TA, Reiter JL, Baron AT, Maihle NJ.

Hybrid Hybridomics. 2002 Jun;21(3):183-9.

PMID:
12165144

Supplemental Content

Loading ...
Support Center